From Bench to Bedside: Immunotherapy for Prostate Cancer
The mainstay therapeutic strategy for metastatic castrate-resistant prostate cancer (CRPC) continues to be androgen deprivation therapy usually in combination with chemotherapy or androgen receptor targeting therapy in either sequence, or recently approved novel agents such as Radium 223. However, i...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2014-01-01
|
Series: | BioMed Research International |
Online Access: | http://dx.doi.org/10.1155/2014/981434 |
id |
doaj-ad5adef30398423790d7e81e37a20cb4 |
---|---|
record_format |
Article |
spelling |
doaj-ad5adef30398423790d7e81e37a20cb42020-11-24T22:29:40ZengHindawi LimitedBioMed Research International2314-61332314-61412014-01-01201410.1155/2014/981434981434From Bench to Bedside: Immunotherapy for Prostate CancerBrian Wan-Chi Tse0Lidija Jovanovic1Colleen Coyne Nelson2Paul de Souza3Carl Andrew Power4Pamela Joan Russell5Australian Prostate Cancer Research Centre-Queensland, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, 37 Kent Street, Brisbane, QLD 4102, AustraliaAustralian Prostate Cancer Research Centre-Queensland, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, 37 Kent Street, Brisbane, QLD 4102, AustraliaAustralian Prostate Cancer Research Centre-Queensland, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, 37 Kent Street, Brisbane, QLD 4102, AustraliaSydney School of Medicine, University of Western Sydney, Ingham Institute for Applied Medical Research, Campbell Street, Sydney, NSW 2170, AustraliaBiological Resources Imaging Laboratory, Lowy Cancer Research Centre, University of New South Wales, High Street, Sydney, NSW 2052, AustraliaAustralian Prostate Cancer Research Centre-Queensland, Institute of Health and Biomedical Innovation, Queensland University of Technology, Translational Research Institute, 37 Kent Street, Brisbane, QLD 4102, AustraliaThe mainstay therapeutic strategy for metastatic castrate-resistant prostate cancer (CRPC) continues to be androgen deprivation therapy usually in combination with chemotherapy or androgen receptor targeting therapy in either sequence, or recently approved novel agents such as Radium 223. However, immunotherapy has also emerged as an option for the treatment of this disease following the approval of sipuleucel-T by the FDA in 2010. Immunotherapy is a rational approach for prostate cancer based on a body of evidence suggesting these cancers are inherently immunogenic and, most importantly, that immunological interventions can induce protective antitumour responses. Various forms of immunotherapy are currently being explored clinically, with the most common being cancer vaccines (dendritic-cell, viral, and whole tumour cell-based) and immune checkpoint inhibition. This review will discuss recent clinical developments of immune-based therapies for prostate cancer that have reached the phase III clinical trial stage. A perspective of how immunotherapy could be best employed within current treatment regimes to achieve most clinical benefits is also provided.http://dx.doi.org/10.1155/2014/981434 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Brian Wan-Chi Tse Lidija Jovanovic Colleen Coyne Nelson Paul de Souza Carl Andrew Power Pamela Joan Russell |
spellingShingle |
Brian Wan-Chi Tse Lidija Jovanovic Colleen Coyne Nelson Paul de Souza Carl Andrew Power Pamela Joan Russell From Bench to Bedside: Immunotherapy for Prostate Cancer BioMed Research International |
author_facet |
Brian Wan-Chi Tse Lidija Jovanovic Colleen Coyne Nelson Paul de Souza Carl Andrew Power Pamela Joan Russell |
author_sort |
Brian Wan-Chi Tse |
title |
From Bench to Bedside: Immunotherapy for Prostate Cancer |
title_short |
From Bench to Bedside: Immunotherapy for Prostate Cancer |
title_full |
From Bench to Bedside: Immunotherapy for Prostate Cancer |
title_fullStr |
From Bench to Bedside: Immunotherapy for Prostate Cancer |
title_full_unstemmed |
From Bench to Bedside: Immunotherapy for Prostate Cancer |
title_sort |
from bench to bedside: immunotherapy for prostate cancer |
publisher |
Hindawi Limited |
series |
BioMed Research International |
issn |
2314-6133 2314-6141 |
publishDate |
2014-01-01 |
description |
The mainstay therapeutic strategy for metastatic castrate-resistant prostate cancer (CRPC) continues to be androgen deprivation therapy usually in combination with chemotherapy or androgen receptor targeting therapy in either sequence, or recently approved novel agents such as Radium 223. However, immunotherapy has also emerged as an option for the treatment of this disease following the approval of sipuleucel-T by the FDA in 2010. Immunotherapy is a rational approach for prostate cancer based on a body of evidence suggesting these cancers are inherently immunogenic and, most importantly, that immunological interventions can induce protective antitumour responses. Various forms of immunotherapy are currently being explored clinically, with the most common being cancer vaccines (dendritic-cell, viral, and whole tumour cell-based) and immune checkpoint inhibition. This review will discuss recent clinical developments of immune-based therapies for prostate cancer that have reached the phase III clinical trial stage. A perspective of how immunotherapy could be best employed within current treatment regimes to achieve most clinical benefits is also provided. |
url |
http://dx.doi.org/10.1155/2014/981434 |
work_keys_str_mv |
AT brianwanchitse frombenchtobedsideimmunotherapyforprostatecancer AT lidijajovanovic frombenchtobedsideimmunotherapyforprostatecancer AT colleencoynenelson frombenchtobedsideimmunotherapyforprostatecancer AT pauldesouza frombenchtobedsideimmunotherapyforprostatecancer AT carlandrewpower frombenchtobedsideimmunotherapyforprostatecancer AT pamelajoanrussell frombenchtobedsideimmunotherapyforprostatecancer |
_version_ |
1725743585646608384 |